Bain Capital Life Sciences Investors, LLC Long-Term Concentrated

CIK: 0001703031 · Show all filings

Period: Q3 2019 (← Previous) (Next →)

Filing Date: Nov 14, 2019

Total Value ($000): $388,402 (100.0% shares, 0.0% debt)

Holdings (7)

— SPRINGWORKS THERAPEUTICS INC 40.6%

Value ($000) $157,859 Shares 7,281,307 Est. Cost $21.68 Unrealized —

— DICERNA PHARMACEUTICALS INC 27.1%

Value ($000) $105,262 Shares 7,330,237 Est. Cost $9.03 Unrealized —

— SOLID BIOSCIENCES INC 10.3%

Value ($000) $40,028 Shares 3,871,164 Est. Cost $8.88 Unrealized —

REPL REPLIMUNE GROUP INC 10.2%

Value ($000) $39,462 Shares 2,838,968 Est. Cost $17.53 Unrealized -30.0%

— DYNAVAX TECHNOLOGIES CORP 7.8%

Value ($000) $30,259 Shares 8,452,235 Est. Cost $3.58 Unrealized —

— APTINYX INC 2.0%

Value ($000) $7,766 Shares 2,225,092 Est. Cost $24.17 Unrealized —

— MARINUS PHARMACEUTICALS INC 2.0%

Value ($000) $7,766 Shares 5,042,735 Est. Cost $7.04 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	SPRINGWORKS THERAPEUTICS INC	7,281,307	$157,859	40.6%	$21.68	—	COM	85205L107
—	DICERNA PHARMACEUTICALS INC	7,330,237	$105,262	27.1%	$9.03	—	COM	253031108
—	SOLID BIOSCIENCES INC	3,871,164	$40,028	10.3%	$8.88	—	COM	83422E105
REPL	REPLIMUNE GROUP INC	2,838,968	$39,462	10.2%	$17.53	-30.0%	COM	76029N106
—	DYNAVAX TECHNOLOGIES CORP	8,452,235	$30,259	7.8%	$3.58	—	COM	268158201
—	APTINYX INC	2,225,092	$7,766	2.0%	$24.17	—	COM	03836N103
—	MARINUS PHARMACEUTICALS INC	5,042,735	$7,766	2.0%	$7.04	—	COM	56854Q101